Literature DB >> 17611560

Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon.

O Ringdén1, M Uzunel, B Sundberg, L Lönnies, S Nava, J Gustafsson, L Henningsohn, K Le Blanc.   

Abstract

Mesenchymal stem cells (MSC) possess anti-inflammatory properties and participate in tissue repair. We used MSC to heal therapy-induced tissue toxicity. Ten consecutive patients, treated with MSC due to tissue toxicity following allogeneic hematopoietic stem cell transplantation, (ASCT) were included. Their median age was 48 (13-64) years. Seven had hemorrhagic cystitis grades 2-5, two had pneumomediastinum and one had perforated colon and peritonitis. MSC donors were mainly third-party, HLA-mismatched (n=11), HLA-haploidentical (n=3) and, in two cases, the HLA-identical ASCT sibling donors. MSC were given intravenously, the median cell dose was 1.0 (range 0.7-2)x10(6)/kg. In five patients, the severe hemorrhagic cystitis cleared after MSC infusion. Gross hematuria disappeared after median 3 (1-14) days. Two patients had reduced transfusion requirements after MSC infusion, but died of multiorgan failure. In one of them, MSC donor DNA was demonstrated in the urinary bladder. In two patients, pneumomediastinum disappeared after MSC infusions. A patient with steroid-resistant graft-versus-host disease of the gut experienced perforated diverticulitis and peritonitis that was reversed twice by MSC. MSC is a novel treatment for therapy-induced tissue toxicity.

Entities:  

Mesh:

Year:  2007        PMID: 17611560     DOI: 10.1038/sj.leu.2404833

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  50 in total

1.  Canine bone marrow-derived mesenchymal stromal cells suppress alloreactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation.

Authors:  Won Sik Lee; Yasuhiro Suzuki; Scott S Graves; Mineo Iwata; G M Venkataraman; Marco Mielcarek; Laura J Peterson; Susumu Ikehara; Beverly Torok-Storb; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-10       Impact factor: 5.742

2.  Uncultured marrow mononuclear cells delivered within fibrin glue hydrogels to porous scaffolds enhance bone regeneration within critical-sized rat cranial defects.

Authors:  James D Kretlow; Patrick P Spicer; John A Jansen; Charles A Vacanti; F Kurtis Kasper; Antonios G Mikos
Journal:  Tissue Eng Part A       Date:  2010-10-12       Impact factor: 3.845

3.  Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro.

Authors:  H Karlsson; T Erkers; S Nava; S Ruhm; M Westgren; O Ringdén
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 4.  Stem cells in sepsis and acute lung injury.

Authors:  Sushma K Cribbs; Greg S Martin
Journal:  Am J Med Sci       Date:  2011-04       Impact factor: 2.378

5.  HSCT recipients have specific tolerance to MSC but not to the MSC donor.

Authors:  Mikael Sundin; A John Barrett; Olle Ringdén; Mehmet Uzunel; Helena Lönnies; Asa-Lena Dackland; Birger Christensson; Katarina Le Blanc
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

6.  Collection, cryopreservation, and characterization of human dental pulp-derived mesenchymal stem cells for banking and clinical use.

Authors:  Brandon C Perry; Dan Zhou; Xiaohua Wu; Feng-Chun Yang; Michael A Byers; T-M Gabriel Chu; J Jeffrey Hockema; Erik J Woods; W Scott Goebel
Journal:  Tissue Eng Part C Methods       Date:  2008-06       Impact factor: 3.056

7.  Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses.

Authors:  Fang Yin; Minoo Battiwalla; Sawa Ito; Xingmin Feng; Fariba Chinian; Jan Joseph Melenhorst; Eleftheria Koklanaris; Marianna Sabatino; David Stroncek; Leigh Samsel; Jeffrey Klotz; Nancy F Hensel; Pamela G Robey; A John Barrett
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

Review 8.  The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.

Authors:  Alexander Rühle; Ramon Lopez Perez; Bingwen Zou; Anca-Ligia Grosu; Peter E Huber; Nils H Nicolay
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

Review 9.  Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions.

Authors:  Jeffery J Auletta; Kenneth R Cooke; Luis A Solchaga; Robert J Deans; Wouter van't Hof
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-16       Impact factor: 5.742

10.  Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells.

Authors:  K English; J M Ryan; L Tobin; M J Murphy; F P Barry; B P Mahon
Journal:  Clin Exp Immunol       Date:  2009-02-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.